DOI: 10.4244/EIJV8I9A170

First-in-human experience: percutaneous renal denervation through a false lumen fenestration in aortic dissection type B

Sebastian Ewen*, MD; Felix Mahfoud, MD; Michael Böhm, MD

A 61-year-old man (height 181 cm, weight 110 kg) presented to our clinic with dyspnoea (NYHA Class II) and progressive chest and abdominal pain. Medical history included an aortic dissection type B with perfusion of the left kidney from the false lumen, diagnosed in 2009 (Figure 1A and Figure 1B). The patient was receiving five antihypertensive drugs (bisoprolol 5 mg ½-0-½, hydrochlorothiazide 25 mg 1-0-0, amlodipine 10 mg 1-0-0, urapidil 90 mg 1-0-1, moxonidine 0.3 mg 1-0-1). Office blood pressure (BP) was 160/95 mmHg. Ambulatory 24-hour BP monitoring confirmed true treatment resistance (mean 141/91 mmHg, non-dipping pattern).

Figure 1. A) Magnetic resonance angiography (MRA) of the aortic arch, showing the entry of the dissection distal of the left subclavian artery. B) MRA, showing the descending aorta with the dissection membrane. Angiography of C) the right renal artery, and D) the left renal artery, before renal denervation (after fenestration).

Renal denervation was performed via femoral access. An 8 Fr IMA guiding catheter (Cordis, Johnson & Johnson, Warren, NJ, USA) was placed into the true aortic lumen at the level of the left renal artery. After a fenestration manoeuvre of the intima flap, performed using an IRON MAN PTCA wire (Abbott Vascular, Redwood City, CA, USA), the Symplicity™ radiofrequency catheter (Medtronic Inc., Minneapolis, MN, USA) was introduced and advanced to the distal segment of the renal artery under fluoroscopy (Figure 1C and Figure 1D, Moving image 1 and Moving image 2). Five treatments of the left artery and six of the right artery were successfully applied.

At three and six-month follow-up, ambulatory 24-hour BP was reduced by 13/10 mmHg and 14/9 mmHg (mean daytime 130/83 mmHg; mean night-time 122/79 mmHg), respectively (Online Figure 1). Six months after treatment, BP was controlled to target (office 130/90 mmHg). MRA showed no sign of complications at six-month follow-up.

Conflict of interest statement

The institution has received scientific support from Medtronic/Ardian. M. Böhm and F. Mahfoud have received speaker honoraria and consultancy fees from Medtronic/Ardian and are supported by Deutsche Forschungsgemeinschaft (KFO 196). F. Mahfoud is supported by Deutsche Hochdruckliga. S. Ewen has no conflicts of interest to declare.

Online data supplement

Online Figure 1. Blood pressure reduction after renal denervation in a patient with aortic dissection type B after three and six months (ambulatory 24-hour blood pressure monitoring).

Moving image 1. Angiography of the right renal artery, before renal denervation (after fenestration).

Moving image 2. Angiography of the left renal artery, before renal denervation (after fenestration).

Online Figure 1. Blood pressure reduction after renal denervation in a patient with aortic dissection type B after three and six months (ambulatory 24-hour blood pressure monitoring).

Supplementary data

To read the full content of this article, please download the PDF.

Moving image 1.
Moving image 2.
Volume 8 Number 9
Jan 18, 2013
Volume 8 Number 9
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV16I1A4 May 20, 2020
Radiofrequency renal denervation is effective – and safe?
Mahfoud F and Kulenthiran S
free

10.4244/EIJV9SRA11 May 21, 2013
Updated ESH position paper on interventional therapy of resistant hypertension
Schmieder R et al
free

10.4244/EIJV14I12A225 Dec 20, 2018
Renal artery denervation: a lot done and more to do
Sharif F
free

10.4244/EIJV9SRA26 May 21, 2013
Potential new indications and future studies
Sudano I et al
free

SPECIAL REPORT

10.4244/EIJY14M12_03 Feb 20, 2015
First-in-man radial access renal denervation with the ReCor Radiance™ catheter
Daemen J and Van Mieghem NM
free
Trending articles
318.3

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
116.85

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
108.3

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
91.6

Image – Interventional flashlight

10.4244/EIJ-D-22-00344 Aug 5, 2022
First dedicated transcatheter leaflet splitting device: the ShortCut device
Tchétché D et al
free
71.3

State-of-the-art

10.4244/EIJ-D-22-00627 Feb 6, 2023
Left atrial appendage occlusion
Holmes D et al
free
68.9

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved